1. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS
    Katsumi Amikura et al, 2017, J Surg Oncol CrossRef
  2. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
    T Yoshino et al, 2018 CrossRef
  3. Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma
    Jianhua Liu et al, 2018, Gastroenterology Research and Practice CrossRef
  4. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer
    Hiroyasu Furuki et al, 2018, European Journal of Surgical Oncology CrossRef
  5. DNA Mismatch Repair in Cancer
    Marina Baretti et al, 2018, Pharmacology & Therapeutics CrossRef
  6. Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells
    Ugo Testa et al, 2018, Medical Sciences CrossRef
  7. Decreased expression of chromodomain helicase DNA-binding protein 9 is a novel independent prognostic biomarker for colorectal cancer
    Li Xu et al, 2018, Braz J Med Biol Res CrossRef
  8. Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
    Chiara Molinari, 0 CrossRef
  9. Biomarker concordance between primary colorectal cancer and its metastases
    D.S. Bhullar et al, 2019, EBioMedicine CrossRef
  10. Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients
    Martina Rebersek et al, 2019 CrossRef
  11. Sequencing of RAS/RAF pathway genes in primary colorectal cancer and matched liver and lung metastases
    Nikki Knijn et al, 2019, Appl Cancer Res CrossRef
  12. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
    Wilhelm Graf et al, 2019, Ann Surg Oncol CrossRef
  13. Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis
    Zu‐Lu Ye et al, 2019, Cancer Med CrossRef
  14. High concordance and negative prognostic impact of RAS/BRAF/PIK3CA mutations in multiple resected colorectal liver metastases
    Tuva Høst Brunsell et al, 2019, Clinical Colorectal Cancer CrossRef
  15. Microsatellite instability: a review of what the oncologist should know
    Kai Li et al, 2020, Cancer Cell Int CrossRef
  16. Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts
    John J Aird et al, 2020, Histopathology CrossRef
  17. Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases
    Yaolin Song et al, 2020, Front. Genet. CrossRef
  18. Redefining Colorectal Cancer by Tumor Biology
    Mohamed E. Salem et al, 2020, American Society of Clinical Oncology Educational Book CrossRef
  19. Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy
    A.  A. Tryakin et al, 2020, Malignant Tumours CrossRef
  20. TRIBE2 results and toxicity
    Jianwei Zhang et al, 2020, The Lancet Oncology CrossRef
  21. Upregulation of c-mesenchymal epithelial transition expression and RAS mutations are associated with late lung metastasis and poor prognosis in colorectal carcinoma
    Jianhua Liu et al, 2018, Exp Ther Med CrossRef
  22. Correlation between microsatellite instability and RAS gene mutation and stage Ⅲ colorectal cancer
    Wenbo Niu et al, 2018, Oncol Lett CrossRef
  23. Metastatic Colorectal Cancer: Prognostic and Predictive Factors
    Anna Nappi et al, 2020, CMC CrossRef
  24. Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer
    Yan Yan et al, 2020, WJGO CrossRef
  25. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.
    Yasmin Kamal et al, 2020, Immunotherapy CrossRef
  26. Diffusion-Weighted MRI and Diffusion Kurtosis Imaging to Detect RAS Mutation in Colorectal Liver Metastasis
    Vincenza Granata et al, 2020, Cancers CrossRef
  27. Genetic Alterations of Metastatic Colorectal Cancer
    Ugo Testa et al, 2020, Biomedicines CrossRef
  28. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A multidimensional analysis
    Yutian Zou et al, 2021, EBioMedicine CrossRef
  29. Radiomics-Derived Data by Contrast Enhanced Magnetic Resonance in RAS Mutations Detection in Colorectal Liver Metastases
    Vincenza Granata et al, 2021, Cancers CrossRef
  30. Histological growth patterns and molecular analysis of resected colorectal lung metastases
    Emanuela Pilozzi et al, 2021, Pathology - Research and Practice CrossRef
  31. Recommendations for Specimen and Therapy Selection in Colorectal Cancer
    Snehal B. Patel et al, 2021, Oncol Ther CrossRef
  32. Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer
    Brian Schulte et al, 2021, Advances in Oncology CrossRef
  33. Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer
    Vegar Johansen Dagenborg et al, 2021, Front. Oncol. CrossRef
  34. Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer
    Andrea Di Giorgio et al, 2021, J Gastrointest Surg CrossRef
  35. Prognostic Factors of Colorectal Cancer: A Comparative Study on Patients With or Without Liver Metastasis
    Honghua Peng et al, 2021, Front. Oncol. CrossRef
  36. Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre)
    Ruba Hamed et al, 2021, Mol Clin Oncol CrossRef
  37. KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
    Flávia Pereira et al, 2022, Cells CrossRef
  38. MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice
    Paola Parente et al, 2022, J Clin Pathol CrossRef
  39. The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases
    Michael P. Flood et al, 2022, European Journal of Surgical Oncology CrossRef
  40. Analysis of KRAS, NRAS, and BRAF Mutations, Microsatellite Instability, and Relevant Prognosis Effects in Patients With Early Colorectal Cancer: A Cohort Study in East Asia
    Yang Li et al, 2022, Front. Oncol. CrossRef
  41. Efficacy of neoadjuvant chemotherapy for initially resectable colorectal liver metastases: A retrospective cohort study
    Kazuhisa Takeda et al, 2022, WJGO CrossRef
  42. Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer and MLH1 mutation
    Melanie Demes et al, 2022, Oncotarget CrossRef
  43. Concurrent loss of MLH1, PMS2 and MSH6 immunoexpression in digestive system cancers indicating a widespread dysregulation in DNA repair processes
    Nic Gabriel Reitsam et al, 2022, Front. Oncol. CrossRef
  44. Molecular Pathology of Gastric Cancer
    Moonsik Kim et al, 2022, J Gastric Cancer CrossRef
  45. High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations
    Jianlei Wang et al, 2022, Front. Oncol. CrossRef
  46. Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer
    Qianpeng Huang et al, 2022 CrossRef
  47. Biomarker concordance between primary colorectal cancer and ovarian metastases: a Dutch cohort study
    Richard van der Meer et al, 2022, J Cancer Res Clin Oncol CrossRef
  48. Development of the Peritoneal Metastasis: A Review of Back-Grounds, Mechanisms, Treatments and Prospects
    Kaijie Ren et al, 2022, JCM CrossRef
  49. Are High Levels of Microsatellite Instability and Microsatellite Stability Identical in DNA Mismatch Repair-Deficient Colorectal Cancer Patients?
    Yan-Yu Qiu et al, 2023, Canadian Journal of Gastroenterology and Hepatology CrossRef
  50. The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) – a real- life data report 2013–2018
    Tanja Mesti et al, 2023 CrossRef
  51. null
    Prince Amoah Barnie et al, 2023 CrossRef
  52. Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications
    Nadia Saoudi González et al, 2023, Cancers CrossRef
  53. VarSCAT: A computational tool for sequence context annotations of genomic variants
    Ning Wang et al, 2023, PLoS Comput Biol CrossRef
  54. KRAS and BRAF Mutation Rates and Survival Outcomes in Colorectal Cancer in an Ethnically Diverse Patient Cohort
    Paul Habashy et al, 2023, IJMS CrossRef
  55. Correlation between NGS panel-based mutation results and clinical information in colorectal cancer patients
    Bo Cheng et al, 2024, Heliyon CrossRef